IR
Superintel
OverviewMarketsWatchlist
© 2026 IR SuperintelMethodologyContact

In8bio Inc (INAB)

CUSIP: 45674E208 | NYSE | Healthcare · Biotechnology | Micro Cap | 34 institutional holders

Quarters

Q3 2026Q2 2026Q1 2026Q4 2025Q3 2025
CompareDetailedHistoricalFundsOptions13D/13GPeersTargetingTrading SummaryProfile

Beneficial Ownership — 13D / 13G

Full history →

5%+ stakes reported outside the quarterly cycle. A 13D is due within five business days of the event below, so these figures lead the holders table until the filer's next 13F catches up to them.

HolderShares% of ClassChangeEvent Datevs 13F
13G/ALytton Laurence W1,056,51310.0%New 5%+ stakeJun 30, 2026No 13F filer matched
13D/AEmily Fairbairn
with Malcom Fairbairn, Malcom and Emily Fairbairn 2010 Crut
215,4312.2%

Institutional Holders — Q3 2026

SBI Securities Co., Ltd.100
0.0% of portfolio›$133
Barclays PLC2
0.0% of portfolio›$3
StyleTurnoverLocationFiled
SBI Securities Co., Ltd.
100$1330.0%Agg GrowthLowTokyo, Mexico2026-10-22
Barclays PLC
2$30.0%CoreMediumLondon, United Kingdom2026-11-06
−517,862
May 27, 2026
No 13F filer matched
13G/ALytton Laurence W1,056,513
10.0% of class · Jun 30, 2026New 5%+ stake
No 13F filer matched
13D/AEmily Fairbairn215,431
2.2% of class · May 27, 2026−517,862
with Malcom Fairbairn, Malcom and Emily Fairbairn 2010 Crut
No 13F filer matched